AJMC August 26, 2024
Medicare has not clearly defined what constitutes “established cardiovascular disease,” leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.
According to a study published today in Annals of Internal Medicine, expanding Medicare coverage for semaglutide could make millions of older Americans newly eligible for the drug, but with the potential to add up to $145 billion annually to federal health care costs; the decision hinges on how broadly “cardiovascular disease” is defined.1
Evolving discussions have been happening with the potential expansion of Medicare coverage for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. Traditionally prescribed for diabetes and weight loss, semaglutide has recently...
Today's Sponsors
Today's Sponsor